Silver Sponsor

IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of cell therapy and immune-based treatments of cancer. Using our secreted proteomic platform to identify patient responses at the single cell level, IsoPlexis' original scientific leaders from Yale, Caltech, UCLA, and Memorial Sloan Kettering Cancer Center are advancing the understanding of personalized therapies against cancer.


Sign Up for Event Updates